Source:http://linkedlifedata.com/resource/pubmed/id/10775881
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2000-8-24
|
pubmed:abstractText |
We describe a new simple, selective and sensitive micromethod based on HPLC and fluorescence detection to measure debrisoquine (D) and 4-hydroxydebrisoquine (4-OHD) in urine for the investigation of xenobiotic metabolism by debrisoquine hydroxylase (CYP2D6). Four hundred microl of urine was required for the analysis of D and 4-OHD. Peaks were eluted at 8.3 min (4-OHD), 14.0 min (D) and 16.6 min for the internal standard, metoprolol (20 microg/ml). The 5-microm CN-reverse-phase column (Shimpack, 250 x 4.6 mm) was eluted with a mobile phase consisting of 0.25 M acetate buffer, pH 5.0, and acetonitrile (9:1, v/v) at 0.7 ml/min with detection at lambdaexcitation = 210 nm and lambdaemission = 290 nm. The method, validated on the basis of measurements of spiked urine, presented 3 ng/ml (D) and 6 ng/ml (4-OHD) sensitivity, 390-6240 ng/ml (D) and 750-12000 ng/ml (4-OHD) linearity, and 5.7/8.2% (D) and 5.3/8.2% (4-OHD) intra/interassay precision. The method was validated using urine of a healthy Caucasian volunteer who received one 10-mg tablet of Declinax(R), po, in the morning after an overnight fast. Urine samples (diuresis of 4 or 6 h) were collected from zero to 24 h. The urinary excretion of D and 4-OHD, Fel (0-24 h), i.e., fraction of dose administered and excreted into urine, was 6.4% and 31.9%, respectively. The hydroxylation capacity index reported as metabolic ratio was 0.18 (D/4-OHD) for the person investigated and can be compared to reference limits of >12.5 for poor metabolizers (PM) and <12.5 for extensive metabolizers (EM). In parallel, the recovery ratio (RR), another hydroxylation capacity index, was 0.85 (4-OHD: SigmaD + 4-OHD) versus reference limits of RR <0.12 for PM and RR >0. 12 for EM. The healthy volunteer was considered to be an extensive metabolizer on the basis of the debrisoquine test.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0100-879X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
509-14
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10775881-Chromatography, High Pressure Liquid,
pubmed-meshheading:10775881-Cytochrome P-450 CYP2D6,
pubmed-meshheading:10775881-Debrisoquin,
pubmed-meshheading:10775881-Female,
pubmed-meshheading:10775881-Fluorometry,
pubmed-meshheading:10775881-Humans,
pubmed-meshheading:10775881-Hydroxylation,
pubmed-meshheading:10775881-Middle Aged,
pubmed-meshheading:10775881-Phenotype,
pubmed-meshheading:10775881-Sensitivity and Specificity,
pubmed-meshheading:10775881-Xenobiotics
|
pubmed:year |
2000
|
pubmed:articleTitle |
A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
|
pubmed:affiliation |
Laboratório de Farmacologia Terapêutica, Unidade 2, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|